TY - JOUR
T1 - Multiple Sklerose Therapie Konsensus Gruppe (MSTKG)
T2 - Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
AU - die Multiple Sklerose Therapie Konsensus Gruppe (MSTKG)
AU - Wiendl, Heinz
AU - Gold, Ralf
AU - Berger, Thomas
AU - Derfuss, Tobias
AU - Linker, Ralf
AU - Mäurer, Mathias
AU - Stangel, Martin
AU - Aktas, Orhan
AU - Baum, Karl
AU - Berghoff, Martin
AU - Bittner, Stefan
AU - Chan, Andrew
AU - Czaplinski, Adam
AU - Deisenhammer, Florian
AU - Di Pauli, Franziska
AU - Du Pasquier, Renaud
AU - Enzinger, Christian
AU - Fertl, Elisabeth
AU - Gass, Achim
AU - Gehring, Klaus
AU - Gobbi, Claudio
AU - Goebels, Norbert
AU - Guger, Michael
AU - Haghikia, Aiden
AU - Hartung, Hans‑Peter ‑P
AU - Heidenreich, Fedor
AU - Hoffmann, Olaf
AU - Hunter, Zoë R.
AU - Kallmann, Boris
AU - Kleinschnitz, Christoph
AU - Klotz, Luisa
AU - Leussink, Verena
AU - Leutmezer, Fritz
AU - Limmroth, Volker
AU - Lünemann, Jan D.
AU - Lutterotti, Andreas
AU - Meuth, Sven G.
AU - Meyding-Lamadé, Uta
AU - Platten, Michael
AU - Rieckmann, Peter
AU - Schmidt, Stephan
AU - Tumani, Hayrettin
AU - Weber, Martin S.
AU - Weber, Frank
AU - Zettl, Uwe K.
AU - Ziemssen, Tjalf
AU - Zipp, Frauke
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/8
Y1 - 2021/8
N2 - Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, Switzerland).
AB - Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, Switzerland).
KW - Autoimmune-mediated disease
KW - Early therapeutic intervention
KW - Guideline
KW - Immunotherapy
KW - Treatment recommendation
UR - http://www.scopus.com/inward/record.url?scp=85111967309&partnerID=8YFLogxK
U2 - 10.1007/s00115-021-01157-2
DO - 10.1007/s00115-021-01157-2
M3 - Review article
C2 - 34297142
AN - SCOPUS:85111967309
SN - 0028-2804
VL - 92
SP - 773
EP - 801
JO - Nervenarzt
JF - Nervenarzt
IS - 8
ER -